Lys25
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Acetylation Site Page:
Lys25 - ACAA2 (human)

Site Information
GAYGGLLkDFTATDL    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: ACAA2 (mouse): K25, ACAA2 (rat): K25
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 461222

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
Disease tissue studied: liver cancer (13, 14), hepatocellular carcinoma (13, 14)
Relevant cell line - cell type - tissue: A549 (pulmonary) (3), HeLa (cervical) (1), HepG2 (hepatic) (13, 14), Jurkat (T lymphocyte) (3), liver (2), OCI-ly3 (B lymphocyte) (7, 9, 11, 12), RC-K8 (B lymphocyte) (8, 10), Reh (B lymphocyte) (4, 5, 6)




References

1

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

2

Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786   Curated Info

3

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

4

(2007) CST Curation Set: 2707; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

5

(2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

6

(2007) CST Curation Set: 2709; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

7

(2007) CST Curation Set: 2510; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

8

(2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

9

(2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

10

(2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

11

(2007) CST Curation Set: 2440; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

12

(2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

13

(2005) CST Curation Set: 868; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

14

(2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.